Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.

The use of sunitinib in dialysis patients is poorly described but is of clinical importance. We report 2 cases of patients receiving sunitinib for metastatic renal cell carcinoma while undergoing dialysis. The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue and hypertension. The second patient underwent peritoneal dialysis and also had significant problems with hypertension. The tolerance of sunitinib in the setting of dialysis can be challenging as these interventions can have synergistic side effects. Close monitoring for toxicity and dosage manipulations might be required if such therapy is attempted.

Written by:
Vickers MM, Heng DY, Hemmelgarn B, Eigl BJ.   Are you the author?

Reference:
Clin Genitourin Cancer. 2009 Oct 1;7(3):E104-E106.

PubMed Abstract
PMID:19815480

UroToday.com Renal Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!